Similar articles

• Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.

  Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Thakkar H, et al. J Biol Chem. 2001 Oct 19;276(42):38361-9. doi: 10.1074/jbc.M103321200. Epub 2001 Jul 18. J Biol Chem. 2001. Retraction in: J Biol Chem. 2002 Aug 16;277(33):30408. PMID: 11461904 Retracted.
• Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.

  Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. Chen X, et al. Oncogene. 2001 Sep 20;20(42):6073-83. doi: 10.1038/sj.onc.1204736. Oncogene. 2001. PMID: 11593415
• Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.

  Yang J, Li G, Zhang K. Yang J, et al. Biomed Pharmacother. 2016 Dec;84:1078-1087. doi: 10.1016/j.biopha.2016.10.028. Epub 2016 Oct 22. Biomed Pharmacother. 2016. PMID: 27780136
• Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.

  Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD. Whang YE, et al. Vitam Horm. 2004;67:409-26. doi: 10.1016/S0083-6729(04)67021-X. Vitam Horm. 2004. PMID: 15110188 Review.
• The molecular mechanisms of TRAIL resistance in cancer cells: help in designing new drugs.

  Wang F, Lin J, Xu R. Wang F, et al. Curr Pharm Des. 2014;20(42):6714-22. doi: 10.2174/1381612820666140929100735. Curr Pharm Des. 2014. PMID: 25269558 Review.